14-3-6　ⓔ文献

  1. 丸山彰一，旭　浩一，他．平成27年度厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 分担研究報告書 疾患登録・調査研究分科会．重点疾患2015年度新規受療患者数：全国アンケート調査，2015; 21–27.

  2. 杉山　斉，佐藤　博，他．腎臓病総合レジストリー (J–RBR/J–KDR) 2015年次報告と経過報告．追加資料：ネフローゼ症候群統計，2016.https://cdn.jsn.or.jp/news/160617_kp-2.pdf

  3. 和田健彦，南学正臣：原発性巣状分節性糸球体硬化症の液性因子に関する最近の動向．日本腎臓学会誌，2014; 56: 478–485.

  4. Wada T, Nangaku M: A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J, 2015; 8; 708–715.

  5. Rovin BH, Caster DJ, et al: Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, 2019; 95: 281–295.

  6. D’Agati VD, Fogo AB, et al: Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis, 2004; 43: 368–382.

  7. Sadowski CE, Lovric S, et al: A single–gene cause in 29.5% of cases of steroid–resistant nephrotic syndrome. J Am Soc Nephrol, 2015; 26: 1279–1289.

  8. Corwin HL, Schwartz MM, et al: The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol, 1988; 8: 85–89.

  9. Remuzzi A, Mazerska M, et al: Three–dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. Kidney Int, 1995; 48: 155–162.

  10. Tune BM, Mendoza SA: Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol, 1997; 8: 824–832.

  11. Cattran DC, Appel GB, et al: A randomized trial of cyclosporine in patients with steroid–resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int, 1999; 56: 2220–2226.

  12. Ponticelli C, Edefonti A, et al: Cyclosporin versus cyclophosphamide for patients with steroid–dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant, 1993; 8: 1326–1332.

  13. Usta M, Ersoy A, et al: Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. J Intern Med, 2003; 253: 329–334.

  14. Muso E, Mune M, et al: Immediate therapeutic efficacy of low–density lipoprotein apheresis for drug–resistant nephrotic syndrome: evidence from the short–term results from the POLARIS Study. Clin Exp Nephrol, 2015; 19: 379–386.

  15. 堺　秀人，黒川　清，他：難治性ネフローゼ症候群 (成人例) の診療指針．日本腎臓学会誌，2002; 44: 751–761.

  16. 丸山彰一，猪阪善隆，他：平成27年度厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 分担研究報告書 ネフローゼ症候群ワーキンググループ (山本陵平らによる解析)，2015; 39–49.